News

NICE has announced it does not recommend use of Opdivo for head and neck cancer.- BMS

Read time: 1 mins

Published:9th Jan 2021

The National Institute for Health and Care Excellence (NICE) has turned down Opdivo (nivolumab), from Bristol Myers Squibb, for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based chemotherapy. In draft guidance, NICE announced that evidence collected in the clinical trial and through its own Cancer Drugs Fund showed that people with SCCHN live longer when treated with Opdivo than with one of three possible treatments in the comparator arm. However the cost-effectiveness estimates for Opdivo were higher than those considered ‘acceptable’ by NICE for the use of NHS resources.

Condition: Head & Neck Cancer

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Initiation of the STELLAR-305 phase II/III pivotal trial evaluating zanzalintinib + pembrolizumab in patients with previously untreated recurrent or metastatic head and neck cancer

Exelixis, Inc. announced the initiation of STELLAR-305, a phase II/III pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

1 mins

Drug news

5-year head & neck cancer survival increased from 45% to 73% in CEL-SCI's target population with Multikine cutting risk of death in half, as presented at leading cancer conference ESMO 2023.

CEL-SCI Corporation announced that it has finalized the selection criteria for the head and neck cancer target population to be treated with the Company’s immunotherapy drug Multikine (Leukocyte Interleukin, Injection)

1 min

Drug news

Update on phase III LEAP-010 trial evaluating Keytruda + Lenvima in patients with certain types of recurrent or metastatic head and neck squamous cell carcinoma.- Merck Inc., + Eisai.

Merck Inc,. known as MSD outside of the United States and Canada, and Eisai, provided an update on the Phase III LEAP-010 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1

1 min

See all news